Study of Intraventricular Cerliponase Alfa for CLN2 Disease
The DOI matches its Crossref record; 16 of the 17 references it cites were found in a registry or an index.
Abstract
Background Recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (CLN2) disease, a rare lysosomal disorder that causes progressive dementia in children. Methods In a multicenter, open-label study, we evaluated the effect of intraventricular infusion of cerliponase alfa every 2 weeks in children with CLN2 disease who were between the ages of 3 and 16 years. Treatment was initiated at a dose of 30 mg, 100 mg, or 300 mg; all the patients then received the 300-mg dose for at least 96 weeks. The primary outcome was the time until a 2-point decline in the score on the motor and language domains of the CLN2 Clinical Rating Scale (which ranges from 0 to 6, with 0 representing no function and 3 representing normal function in each of the two domains), which was compared with the time until a 2-point decline in 42 historical controls. We also compared the rate of decline in the motor-language score between the two groups, using data from baseline to the last assessment with a score of more than 0, divided by the length of follow-up (in units of 48 weeks). Results Twenty-four patients were enrolled, 23 of whom constituted the efficacy population. The median time until a 2-point decline in the motor-language score was not reached for treated patients and was 345 days for historical controls. The mean (±SD) unadjusted rate of decline in the motor-language score per 48-week period…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Precision therapy using intracerebroventricular enzyme replacement with recombinant human tripeptidyl peptidase 1 slowed disease progression in one study 148 .”
From Developmental and epileptic encephalopathies (2024) · cites this paper as [148]
Citations
Cites
Sleat, D. E., Donnelly, R. J., Lackland, H., Liu, C.-G., Sohar, I., Pullarkat, R. K., & Lobel, P. (1997) · Science · doi:10.1126/science.277.5333.1802 · Cited by 581
NCL diseases - clinical perspectives
Schulz, A., Kohlschütter, A., Mink, J., Simonati, A., & Williams, R. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.04.008 · Cited by 246
Self-citationSleat, D. E., Gin, R. M., Sohar, I., Wisniewski, K., Sklower-Brooks, S., Pullarkat, R. K., Palmer, D. N., Lerner, T. J., Boustany, R.-M., Uldall, P., et al. (1999) · The American Journal of Human Genetics · doi:10.1086/302427 · Cited by 178
Steinfeld, R., Heim, P., von Gregory, H., Meyer, K., Ullrich, K., Goebel, H. H., & Kohlschütter, A. (2002) · American Journal of Medical Genetics · doi:10.1002/ajmg.10660 · Cited by 178
Self-citationThe Genetic Spectrum of Human Neuronal Ceroid‐lipofuscinoses
Mole, S. (2004) · Brain Pathology · doi:10.1111/j.1750-3639.2004.tb00500.x · Cited by 115
Neurological deterioration in late infantile neuronal ceroid lipofuscinosis
Worgall, S., Kekatpure, M. V., Heier, L., Ballon, D., Dyke, J. P., Shungu, D., Mao, X., Kosofsky, B., Kaplitt, M. G., Souweidane, M. M., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000267885.47092.40 · Cited by 112
Self-citationKatz, M. L., Coates, J. R., Sibigtroth, C. M., Taylor, J. D., Carpentier, M., Young, W. M., Wininger, F. A., Kennedy, D., Vuillemenot, B. R., & O'Neill, C. A. (2014) · Journal of Neuroscience Research · doi:10.1002/jnr.23423 · Cited by 100
Kishnani, P. S., Dickson, P., Muldowney, L., Lee, J. J., Rosenberg, A. S., Abichandani, R., Bluestone, J. A., Burton, B. K., Dewey, M. C., Freitas, A., et al. (2015) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2015.11.001 · Cited by 95
Vuillemenot, B. R., Katz, M. L., Coates, J. R., Kennedy, D., Tiger, P. M. N., Kanazono, S., Lobel, P., Sohár, I., Xu, S., Cahayag, R., et al. (2011) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2011.06.018 · Cited by 81
Vuillemenot, B. R., Kennedy, D., Cooper, J. D., Wong, A. M. S., Sri, S., Doeleman, T., Katz, M. L., Coates, J. R., Johnson, G. C., Reed, R. P., et al. (2014) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2014.09.004 · Cited by 60
Research works printed but not linked: 1
- Mole SE, Williams RE, Goebe HH, eds. The neuronal ceroid lipofuscinoses (Batten disease). 2nd ed. Oxford, England: Oxford University Press, 2011.
Cited by
Items 201–300 of 498
Mitchell, N. L., Murray, S. J., Wellby, M. P., Barrell, G. K., Russell, K. N., Deane, A. R., Wynyard, J. R., Palmer, M. J., Pulickan, A., Prendergast, P. M., et al. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1212228 · Cited by 13
Future perspectives: What lies ahead for Neuronal Ceroid Lipofuscinosis research?
Cooper, J. D., & Mole, S. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165681 · Cited by 13
Bassal, M., Liu, J., Jankowiak, W., Säftig, P., & Bartsch, U. (2021) · Cells · doi:10.3390/cells10030696 · Cited by 13
“Of note, the significant attenuation of disease progression has also been observed in a recent clinical trial on CLN2 patients treated biweekly with intracerebroventricular injections of recombinant TPP1 [103].”
BackgroundKohlschütter, A., & van den Bussche, H. (2019) · Zeitschrift für Evidenz Fortbildung und Qualität im Gesundheitswesen · doi:10.1016/j.zefq.2019.02.008 · Cited by 13
Self-citationBonkowsky, J. L., deVeber, G., Kosofsky, B. E., Augustine, E. F., Bassuk, A. G., Brooks‐Kayal, A. R., Felling, R. J., Fullerton, H. J., Glass, H. C., Grinspan, Z. M., et al. (2020) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2020.08.012 · Cited by 14
Active immunotherapy and alternative therapeutic modalities for Alzheimer's disease
Weninger, S. C., Sperling, B., Alexander, R., Ivarsson, M., Menzies, F. M., Powchik, P., Weber, C. J., Altar, C. A., Crystal, R. G., Haggarty, S. J., et al. (2020) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12090 · Cited by 15
Papandreou, A., Doykov, I., Śpiewak, J., Komarov, N., Habermann, S., Kurian, M. A., Mills, P. B., Mills, K. A., Gissen, P., & Heywood, W. (2022) · Developmental Medicine & Child Neurology · doi:10.1111/dmcn.15334 · Cited by 14
Self-citationLysosomal sialidase NEU1, its intracellular properties, deficiency, and use as a therapeutic agent
Itoh, K., & Tsukimoto, J. (2023) · Glycoconjugate Journal · doi:10.1007/s10719-023-10135-6 · Cited by 12
“Real world effectiveness of cerliponase alfa in classical and atypical patients. A case series”
Segura, O. M. E., Hernández, Z., Mancilla, N., Flórez, R. A. N., & Tavera, L. M. (2021) · Molecular Genetics and Metabolism Reports · doi:10.1016/j.ymgmr.2021.100718 · Cited by 13
Novel treatments in epilepsy guided by genetic diagnosis
Marini, C., & Giardino, M. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15139 · Cited by 14
“with recombinant human tripeptidyl peptidase (Table 2).(49,76) This treatment has been associated with a slowing or even stabilization of the deterioration in gait and language ability.”
MethodHammon, K., de Hart, G., Vuillemenot, B. R., Kennedy, D., Musson, D. G., O’neill, C. A., Katz, M. L., & Henshaw, J. W. (2021) · Clinical and Translational Science · doi:10.1111/cts.13028 · Cited by 12
Levenson, M. S., He, W., Chen, L., Dharmarajan, S. H., Izem, R., Meng, Z., Pang, H., & Rockhold, F. W. (2022) · Statistics in Biopharmaceutical Research · doi:10.1080/19466315.2022.2120533 · Cited by 14
Developmental and epileptic encephalopathies – therapeutic consequences of genetic testing
Syrbe, S. (2022) · Medizinische Genetik · doi:10.1515/medgen-2022-2145 · Cited by 18
“Protein replacement/enzyme replacement therapy Intrathecal enzyme replacement therapy for neuronal ceroid lipofuscinosis [61] Gene therapy (ASO, CRISPR/Cas9, gene replacement therapy) Several novel concepts are on the horizon and await first-in-man studies.”
BackgroundKick, G. R., Whiting, R. E. H., Ota‐Kuroki, J., Castaner, L. J., Morgan-Jack, B. R., Sabol, J. C., Meiman, E. J., Ortiz, F., & Katz, M. L. (2022) · Experimental Eye Research · doi:10.1016/j.exer.2022.109344 · Cited by 12
Panjeshahi, S., Karimzadeh, P., Movafagh, A., Ahmadabadi, F., Rahimian, E., Alijanpour, S., & Miryounesi, M. (2023) · Human Genetics · doi:10.1007/s00439-023-02556-y · Cited by 14
Mitchell, N. L., Russell, K. N., Barrell, G. K., Tammen, I., & Palmer, D. N. (2023) · Developmental Neurobiology · doi:10.1002/dneu.22918 · Cited by 12
Clinical and biochemical footprints of inherited metabolic diseases. XV. Epilepsies
Latzer, I. T., Blau, N., Ferreira, C. R., & Pearl, P. L. (2023) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2023.107690 · Cited by 14
Iwan, K., Patel, N., Heslegrave, A., Borisova, M., Lee, L., Bower, R., Mole, S., Mills, P. B., Zetterberg, H., Mills, K. A., et al. (2021) · F1000Research · doi:10.12688/f1000research.54556.1 · Cited by 12
Self-citationElectrophysiological Biomarkers in Genetic Epilepsies
Armstrong, C., & Marsh, E. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01132-4 · Cited by 9
Brain transcriptome analysis of a CLN2 mouse model as a function of disease progression
Domowicz, M. S., Chan, W., Vázquez, P. N. C., Gonzalez, T., & Schwartz, N. B. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02302-z · Cited by 12
“Recent FDA-approved enzyme replacement therapy, currently the only available treatment, involves intracerebroventricular application of a recombinant human form of TPP1 (BrineuraR, cerliponase alpha) and results in reduction of the motor-language score after 48 and 96 weeks of treatment [8].”
BackgroundEl‐Hage, N., Haney, M. J., Zhao, Y., Rodriguez, M., Wu, Z., Liu, M., Swain, C. J., Yuan, H., & Batrakova, E. V. (2023) · Cells · doi:10.3390/cells12111497 · Cited by 12
“Unfortunately, the therapeutic efficacy diminished over time [4].”
BackgroundTreatable inherited metabolic epilepsies
Latzer, I. T., & Pearl, P. L. (2024) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2024.109621 · Cited by 11
Searching for novel biomarkers using a mouse model of CLN3-Batten disease
Timm, D. J., Cain, J. T., Geraets, R. D., White, K. A., Koh, S. Y., Kielian, T., Pearce, D. A., Hastings, M. L., & Weimer, J. M. (2018) · PLoS ONE · doi:10.1371/journal.pone.0201470 · Cited by 11
Puhl, A. C., & Ekins, S. (2022) · GEN Biotechnology · doi:10.1089/genbio.2021.0013 · Cited by 12
“26 ERT clearly improves health-related quality-of-life declines as the disease progresses.”
Perampanel attenuates myoclonus in a patient with neuronal ceroid lipofuscinoses type 2 disease
Wong, L., Hsu, C., & Lee, W. (2019) · Brain and Development · doi:10.1016/j.braindev.2019.05.001 · Cited by 11
MRI in CLN2 disease patients: Subtle features that support an early diagnosis
Aydın, K., Havalı, C., Kartal, A., Serdaroğlu, A., & Haspolat, Ş. (2020) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2020.07.009 · Cited by 11
Design, Conduct, and Analysis of Externally Controlled Trials
Liu, J., Yao, M., Wang, M., Jie, W., Liu, Y., Luo, X., Huan, J., Deng, K., Deng, K., Zou, K., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.30277 · Cited by 10
Kadbhane, A., Patel, M., Srivastava, S., Singh, P. K., Madan, J., Singh, S. B., & Khatri, D. K. (2021) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2021.102526 · Cited by 10
Morsy, A., Carmona, A. V., & Trippier, P. C. (2021) · Molecules · doi:10.3390/molecules26206235 · Cited by 11
“The administration of rhTPP1 is performed through catheters implanted in the lateral ventricle (intracerebroventricular) and delivered every other week [35].”
MethodBartsch, U., & Storch, S. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.866983 · Cited by 12
“An enzyme replacement therapy (ERT) using the intracerebroventricular infusions of recombinant TPP1 (cerliponase alfa) every 2 weeks has been shown to decelerate the disease progression and was recently approved for the treatment of patients with CLN2 disease (16).”
MethodGrabowski, G. A., & Mistry, P. K. (2022) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2022.07.014 · Cited by 11
Cynomolgus macaque model of neuronal ceroid lipofuscinosis type 2 disease
Munesue, Y., Ageyama, N., Kimura, N., Takahashi, I., Nakayama, S., Okabayashi, S., Katakai, Y., Hiroshi, K. O. I. E., Yagami, K., Ishii, K., et al. (2023) · Experimental Neurology · doi:10.1016/j.expneurol.2023.114381 · Cited by 10
Lysosomal storage disorders: Clinical and therapeutic aspects
Pastores, G. M. (2023) · Handbook of clinical neurology · doi:10.1016/b978-0-323-98817-9.00006-5 · Cited by 10
Sudrié‐Arnaud, B., Snanoudj, S., Dabaj, I., Dranguet, H., Abily-Donval, L., Lebas, A., Vézain, M., Héron, B., Marié, I., Duval-Arnould, M., et al. (2021) · Diagnostics · doi:10.3390/diagnostics11020294 · Cited by 10
“To be efficient, this treatment had to be implemented before psychomotor regression [38].”
MethodArdıçlı, D., Haliloğlu, G., Göçmen, R., Günbey, C., & Topçu, M. (2021) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2021.05.015 · Cited by 10
Evolving therapies in neuronopathic LSDs: opportunities and challenges
Rajan, D. S., & Escolar, M. L. (2022) · Metabolic Brain Disease · doi:10.1007/s11011-022-00939-0 · Cited by 10
“In 2018, cerliponase alfa was approved based on clinical trials in patients with late infantile neuronal ceroid lipofuscinosis (CLN2) (Schulz et al. 2018).”
MethodInfluentialPapandreou, A., Soo, A. K. S., Spaull, R., Mankad, K., Kurian, M. A., & Sudhakar, S. V. (2022) · American Journal of Neuroradiology · doi:10.3174/ajnr.a7693 · Cited by 10
Batten disease through different in vivo and in vitro models: A review
Nittari, G., Tomassoni, D., Roy, P., Martinelli, I., Tayebati, S. K., & Amenta, F. (2022) · Journal of Neuroscience Research · doi:10.1002/jnr.25147 · Cited by 11
First in man study of intravitreal tripeptidyl peptidase 1 for CLN2 retinopathy
Wawrzynski, J. R., Rodriguez-Martinez, A. C., Thompson, D., Ram, D., Bowman, R. J. C., Whiteley, R., Gan, C., Harding, L., Mortensen, A., Mills, P. B., et al. (2023) · Eye · doi:10.1038/s41433-023-02859-4 · Cited by 10
“There is no FDA/EMA approved disease modifying treatment for any form of Batten disease, with the exception of Neuronal Ceroid Lipofuscinosis type 2 (CLN2), for which the intracerebroventricular drug cerliponase alfa was approved in 2017 [2].”
BackgroundMethodInfluentialSelf-citationBreuillard, D., Ouss, L., Normand, M. L., Saint-Denis, T. D., Barnérias, C., Robert, M. P. A., Eisermann, M., Boddaert, N., Caillaud, C., Bahi‐Buisson, N., et al. (2024) · European Journal of Neurology · doi:10.1111/ene.16324 · Cited by 9
“This treatment has resulted in less decline in motor and language function [2, 3].”
BackgroundGuerrini, R., Scheffer, I. E., & Balestrini, S. (2025) · The Lancet Neurology · doi:10.1016/s1474-4422(25)00032-8 · Cited by 10
Schulz, A., Jain, M. M., Butt, T., Ballinger, R., Eliasson, L., Macey, J., Peasgood, T., Olaye, A., Terzakis-Snyder, I.-A., Dyck, I., et al. (2020) · Journal of Inborn Errors of Metabolism and Screening · doi:10.1590/2326-4594-jiems-2019-0013 · Cited by 10
“Replacement of the deficient enzyme (using cerliponase alfa; Brineura®), has been found to slow decline in motor and language function in patients with CLN2 disease [13] and, following completion of the study reported here, this therapy was approved for use by the Food and Drug Administration (FDA) [14] and European M…”
MethodSelf-citationPräzisionsmedizin für genetische Epilepsien – am Anfang des Weges?
Syrbe, S. (2021) · Clinical Epileptology · doi:10.1007/s10309-021-00409-0 · Cited by 9
“stellt eine spezifische Therapie zur Verhinderung einer weiteren Krankheitsprogression dar [16].”
BackgroundSilva, P. J., Janjan, N. A., Ramos, K. S., Udeani, G., Zhong, L., Ory, M. G., & Smith, M. L. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1198088 · Cited by 11
“The only practical control was to compare to disease progression in a historical standard of care cohort (7) using a curated global registry enabled this approach to clinical validation with cerliponase alfa (8).”
MethodWannemacher, R., Jubran, L., Zdora, I., Leitzen, E., Röhn, K., Sippel, V., Paschen, C., Blattmann, P., Baumgärtner, W., Gerhauser, I., et al. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.106917 · Cited by 9
“…substantial benefits and slowing clinical disease progression, this treatment was frequently accompanied by adverse events including convulsions, pyrexia, vomiting, hypersensitivity reactions, failure of the intraventricular application device and bacterial infections (Schulz et al., 2018).”
Proceedings of the 15th Antiepileptic Drug and Device Trials Meeting: State of the Science
Boada, C. M., French, J. A., & Dumanis, S. B. (2020) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2020.107189 · Cited by 10
“85 less than the historical control group [61].”
BackgroundTreating epilepsy with options other than antiepileptic medications
Muthaffar, O. Y. (2020) · Neurosciences · doi:10.17712/nsj.2020.4.20200010 · Cited by 10
Nanotechnology in gene delivery for neural regenerative medicine
Shahlaei, M., Asl, S. M., & Saeidifar, M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-820223-4.00005-x · Cited by 9
Eaton, S. L., Murdoch, F., Rzechorzek, N. M., Thompson, G., Hartley, C., Blacklock, B. T., Proudfoot, C., Lillico, S. G., Tennant, P., Ritchie, A., et al. (2022) · Cells · doi:10.3390/cells11172641 · Cited by 10
“This led to Brineura obtaining Food and Drug Administration (FDA) approval in a significantly shorter timeframe [88].”
BackgroundTreatment of neurometabolic epilepsies: Overview and recent advances
Latzer, I. T., & Pearl, P. L. (2023) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2023.109181 · Cited by 9
Spaull, R., Soo, A. K. S., Batzios, S. P., Footitt, E. J., Whiteley, R., Mink, J. W., Carr, L., Gissen, P., & Kurian, M. A. (2024) · Neurology · doi:10.1212/wnl.0000000000209615 · Cited by 9
Self-citationGaur, P., Gissen, P., Biswas, A., Mankad, K., Sudhakar, S. V., D’Arco, F., Schulz, A., Fiehler, J., Sedlacik, J., & Löbel, U. (2024) · American Journal of Neuroradiology · doi:10.3174/ajnr.a8408 · Cited by 10
Self-citationIntravitreal enzyme replacement for inherited retinal diseases
Rodriguez-Martinez, A. C., Wawrzynski, J. R., & Henderson, R. (2023) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000001029 · Cited by 8
“A significant subcon-junctival haemorrhage happened in one patient after his first intravitreal injection.”
BackgroundSchiffmann, R. (2025) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.70034 · Cited by 10
Tchaicha, S., Auvin, S., Beniczky, S., Brunklaus, A., Lagae, L., Perucca, E., Surges, R., Adler, S., Helmstaedter, C., Jansen, F. E., et al. (2026) · Epilepsia Open · doi:10.1002/epi4.70210 · Cited by 8
“118,130 Well-designed syndrome-specific registries can be highly valuable in establishing a set of historical controls to be used in this context.”
Self-citationCerliponase alfa for CLN2 disease, a promising therapy
Aylward, S. C., Pindrik, J., Abreu, N. J., Cherny, W. B., O’Neal, M. E., & Reyes, E. D. L. (2020) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2020.1856654 · Cited by 9
Genetic and clinical landscape of childhood cerebellar hypoplasia and atrophy
Sakamoto, M., Iwama, K., Sasaki, M., Ishiyama, A., Komaki, H., SAITO, T. K., Takeshita, E., Shimizu‐Motohashi, Y., Haginoya, K., Kobayashi, T., et al. (2022) · Genetics in Medicine · doi:10.1016/j.gim.2022.08.007 · Cited by 8
Collier, A. M., Nemtsova, Y., Kuber, N., Banach-Petrosky, W. A., Modak, A., Sleat, D. E., Nanda, V., & Lobel, P. (2020) · Biochemical Journal · doi:10.1042/bcj20190874 · Cited by 8
“recombinant human TPP1 to the cerebrospinal fluid of patients, resulting in a stabilization of clinical parameters compared to untreated patients (18).”
BackgroundShematorova, E. K., & Shpakovski, G. V. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218055 · Cited by 9
“It is possible that only gene therapy using adenovirus-based vectors can bring some positive effect(s), as was observed in the case of enzyme replacement therapy for Jansky-Bielschowsky disease (NCL2) caused by mutations in the CLN2 gene [90].”
BackgroundMethodMaeser, S., Petre, B. A., Ion, L., Rawer, S., Kohlschütter, A., Santorelli, F. M., Simonati, A., Schulz, A., & Przybylski, M. (2020) · Journal of Mass Spectrometry · doi:10.1002/jms.4675 · Cited by 8
“Patients suffering from NCLs were diagnosed at the University Medical Center Hamburg-Eppendorf, Children's Hospital, Hamburg, Germany and the Department of Molecular Medicine, IRCCS Stella Maris Hospital, Pisa, Italy.7,8,19 Diagnoses were confirmed both clinically and genetically and included four patients with NCL1 (…”
BackgroundSelf-citationHorii, Y., Iniwa, T., Onitsuka, M., Tsukimoto, J., Tanaka, Y., Ike, H., Fukushi, Y., Ando, H., Takeuchi, Y., Nishioka, S.-I., et al. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.04.001 · Cited by 10
González-Sánchez, M., Ramírez-Expósito, M. J., & Martínez-Martos, J. M. (2025) · Neurology International · doi:10.3390/neurolint17070098 · Cited by 8
“Alternative administration routes, such as direct injection into the cerebrospinal fluid or intrathecal injections, have shown potential therapeutic effects [131,137,138].”
Magnetic resonance brain volumetry biomarkers of CLN2 Batten disease identified with miniswine model
Knoernschild, K., Johnson, H. J., Schroeder, K. E., Swier, V. J., White, K. A., Sato, T. S., Rogers, C. S., Weimer, J. M., & Sieren, J. C. (2023) · Scientific Reports · doi:10.1038/s41598-023-32071-z · Cited by 7
Ammendolia, I., Sframeli, M., Esposito, E., Cardia, L., Noto, A., Currò, M., Calapai, G., Pasquale, M. D., Mannucci, C., & Calapai, F. (2024) · Pharmaceuticals · doi:10.3390/ph17111513 · Cited by 7
“Serious adverse events detected in this study included failure of the intraventricular device and device-related infections [16].”
InfluentialA survival analysis of ventricular access devices for delivery of cerliponase alfa
Craven, C. L., Gissen, P., Bower, R., Lee, L., Aquilina, K., & Thompson, D. N. P. (2021) · Journal of Neurosurgery Pediatrics · doi:10.3171/2021.7.peds21129 · Cited by 7
Self-citationMeiman, E. J., Kick, G. R., Jensen, C. A., Coates, J. R., & Katz, M. L. (2022) · Developmental Neurobiology · doi:10.1002/dneu.22878 · Cited by 7
“…of enzyme replacement therapy using a Dachshund model for this disorder led to the successful application of this approach for treating children with CLN2 disease (Katz et al., 2014; Lewis et al., 2019; Schaefers et al., 2021; Schulz et al., 2018; Vuillemenot et al., 2015; Whiting et al., 2014).”
MethodEstablished and Emerging Treatments for Patients with Inborn Errors of Metabolism
Breilyn, M. S., & Wasserstein, M. (2020) · NeoReviews · doi:10.1542/neo.21-10-e699 · Cited by 7
Sun, A., Chang, I. J., Lam, C. T., & Berry, G. T. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-812535-9.00014-5 · Cited by 11
Kovács, A., González-Hernández, J. L., & Pearce, D. A. (2023) · Scientific Reports · doi:10.1038/s41598-023-46283-w · Cited by 6
Current Advances in Clinical Trials for Rare Disease Populations: Spotlight on the Patient
Winter, E., & Schliebner, S. (2021) · Current Clinical Pharmacology · doi:10.2174/1574884716666210316120615 · Cited by 6
Pacemaker Implantation in Juvenile Neuronal Ceroid Lipofuscinosis (CLN3)–A Long-Term Follow-Up Study
Handrup, M. M., Mølgaard, H., Andersen, B. N., & Østergaard, J. R. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.846240 · Cited by 6
“Nevertheless, we know from the progress in CLN2 treatment that therapy may only be effective in some organ systems (13).”
BackgroundThe LINCE Project: A Pathway for Diagnosing NCL2 Disease
Rodrigues, D., de Castro, M. J., Crujeiras, P., Rodríguez, A. D., Marco, A. V., del Toro, M., Couce, M. L., & Colón, C. (2022) · Frontiers in Pediatrics · doi:10.3389/fped.2022.876688 · Cited by 6
“Early administration of cerliponase alfa has led to a significant reduction in the rate of decline of motor and language functions (20), thus delaying disease progression.”
BackgroundTreatment of CLN1 disease with a blood-brain barrier penetrating lysosomal enzyme
Hahn, A., Sato, Y., Ikeda, T., Sonoda, H., Schmidt, M., Pfrimmer, C., Boado, R. J., & Pardridge, W. M. (2022) · Molecular Genetics and Metabolism Reports · doi:10.1016/j.ymgmr.2022.100930 · Cited by 6
Guelbert, N. B., Segura, O. M. E., Amoretti, C. F., Arteaga, A. A., Atanacio, N. G., Bazan, N. S., Carvalho, E. D. F., de Andrade, M. D. F. C., Denzler, I. M., Durand, C., et al. (2024) · Molecular Genetics and Metabolism Reports · doi:10.1016/j.ymgmr.2024.101060 · Cited by 8
“Delayed initiation of disease-modifying therapies was found, with a potentially negative effect on patient quality of life and survival, with deterioration between diagnosis and therapy initiation [9,27,28,30].”
BackgroundResultInfluentialThe Impact of Non-Seizure Symptoms in Dravet Syndrome and Lennox–Gastaut Syndrome
Roberts, E. (2024) · EMJ Neurology · doi:10.33590/emjneurol/11000017 · Cited by 6
“70 In this context, adaptations of current metrics that have already been validated over the last decades are of interest.”
Fyke, Z., Johansson, R., Scott, A. I., Wiley, D., Chelsky, D., Zak, J. D., Al-Nakouzi, N., Koster, K. P., & Yoshii, A. (2024) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2024.108537 · Cited by 7
Ebert, E. T., Schwinghamer, K., & Siahaan, T. J. (2024) · Life · doi:10.3390/life14111456 · Cited by 10
“…transcytosis, peptide-mediated BBB modulation, and intranasal delivery methods have been investigated to deliver neurotrophic factors to the brain [26]; however, some of them have not gone beyond the preclinical stage and need validation for use in humans (for an excellent review, see Whelan et…”
Visual system pathology in a canine model of CLN5 neuronal ceroid lipofuscinosis
Kick, G. R., Meiman, E. J., Sabol, J. C., Whiting, R. E. H., Ota‐Kuroki, J., Castaner, L. J., Jensen, C. A., & Katz, M. L. (2021) · Experimental Eye Research · doi:10.1016/j.exer.2021.108686 · Cited by 6
Kovacs, K. D., Orlin, A., Sondhi, D., Kaminsky, S. M., D’Amico, D. J., Crystal, R. G., & Kiss, S. (2021) · Translational Vision Science & Technology · doi:10.1167/tvst.10.8.23 · Cited by 6
Ocular Manifestations of Neuronal Ceroid Lipofuscinoses
Singh, R. B., Gupta, P., Kartik, A., Farooqui, N., Singhal, S., Shergill, S., Singh, K. P., & Agarwal, A. K. (2021) · Seminars in Ophthalmology · doi:10.1080/08820538.2021.1936571 · Cited by 7
“Recent studies have shown that though previously thought otherwise, retinal degeneration and neuronal degeneration occur independently.(55) The manifestations are usually limited to the posterior segment, and no anterior segment manifestation has been reported in the literature.”
BackgroundMovement Disorders and Inherited Metabolic Disorders: Recognition, Understanding, Improving Outcomes
(2020) · Cambridge University Press eBooks · doi:10.1017/9781108556767 · Cited by 10
Vanier, M. T., Caillaud, C., & Levade, T. (2022) · Springer eBooks · doi:10.1007/978-3-662-63123-2_40 · Cited by 8
Boop, S. H., Nistal, D. A., Barrios-Anderson, A., Cherny, W. B., Chang, I. J., Shelkowitz, E., Kho, T., Goldstein, H. E., & Hauptman, J. S. (2025) · Child s Nervous System · doi:10.1007/s00381-025-06822-4 · Cited by 5
“This drug is also the first approved enzyme replacement therapy administered via extended duration intracere-broventricular (ICV) infusion [4].”
Corti, S., Kim, K. H., Chen, T., Botezatu, A., Cora, V., Ma, K., Pashkovskaia, N., Vergara, A. B., Sperlich, D., Dave, K., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102244 · Cited by 10
Priglinger, C., Courage, C., Lotz-Havla, A. S., Gerhardt, M. J., Ehrt, O., Kurz, M., Pudritz, H., Rudolph, G., Jackson, C. B., & Maier, E. M. (2025) · Neuropediatrics · doi:10.1055/a-2510-5592 · Cited by 5
“8,9 However, the treatment has no effect on CLN2 retinopathy, most likely because the enzyme does not cross the lamina cribrosa and blood – retinal – brain barrier.”
Open-label evaluation of oral trehalose in patients with neuronal ceroid lipofuscinoses
Vecchia, S. D., Gammaldi, N., Ricca, I., Mero, S., Doccini, S., Ardissone, A., Bagnoli, S., Battini, R., Colombi, E., Favaro, J., et al. (2025) · Journal of Neurology · doi:10.1007/s00415-024-12790-7 · Cited by 5
“Apart from a recombinant enzyme replacement therapy approved for CLN2 [9], there are, as yet, no approved drugs or gene therapies capable of modifying the natural history and progression of NCLs, leaving symptomatic and palliative care as the only possible options.”
Self-citationDrug–device combinations in rare diseases: Challenges and opportunities
Tãtaru, E.-A., Dooms, M. M., Gonzaga-Jauregui, C. G., Pasmooij, A. M. G., O’Connor, D. J., & Jonker, A. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104343 · Cited by 5
Incorporation of real-world data to a clinical trial: use of external controls
Kim, T., Park, S., & Shin, K. (2022) · Translational and Clinical Pharmacology · doi:10.12793/tcp.2022.30.e14 · Cited by 6
“This single-arm trial incorporating external control showed that cerliponase alfa treatment in patients with CLN2 disease was able to slow down the decline in motor and language function compared to that in historical controls [19,26].”
ResultBuffy Coat Score as a Biomarker of Treatment Response in Neuronal Ceroid Lipofuscinosis Type 2
Sivananthan, S., Lee, L., Anderson, G. W., Csányi, B., Williams, R. E., & Gissen, P. (2023) · Brain Sciences · doi:10.3390/brainsci13020209 · Cited by 5
“However, assessments of therapeutic effect have been largely limited to clinical observational measures, namely the CLN2 rating scale [31,34].”
BackgroundMethodResultSelf-citationFeofanova, E. V., Zhang, G., Lhatoo, S. D., Metcalf, G., Boerwinkle, E., & Venner, E. (2021) · JMIR Research Protocols · doi:10.2196/25576 · Cited by 5
Retinal degeneration in mice and humans with neuronal ceroid lipofuscinosis type 8
Salpeter, E. M., Leonard, B. C., Lopez, A. J., Murphy, C. J., Thomasy, S. M., Imai, D. M., Grimsrud, K., Lloyd, K. C. K., Yan, J., Russo, R. S., et al. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-4739 · Cited by 5
“, Novato, CA, USA), for treatment of CLN2 (12,13).”
Ho, M., Wirrell, E. C., Petropoulou, K. A., Sakonju, A., Chu, D., Seratti, G., & Palasis, S. (2022) · Journal of Child Neurology · doi:10.1177/08830738221128773 · Cited by 5
Sortilin inhibition treats multiple neurodegenerative lysosomal storage disordersPreprint
Leppert, H. G., Anderson, J. T., Timm, K. J., Davoli, C., Pratt, M. A., Booth, C. D., White, K. A., Rechtzigel, M. J., Meyerink, B. L., Johnson, T. B., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.09.22.559064 · Cited by 5
Alam†, M. S., Khatiwada, A., Eaton, S. L., Cohen, D. M., White, J., Derby, M., Peterson, D., Rivera-Pena, G., Nayal, M., Becker, M., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.07.011 · Cited by 5
“8,9 In CLN1, ERT halted disease progression in rodents and demonstrated partial preservation of brain morphology in Ppt1 (cid:0) / (cid:0) sheep.”
CLN2 Disease: Current Understandings, Challenges, and Future Directions
Shock, M., Nigro, E., Donner, E. J., & Whitney, R. (2025) · Journal of Child Neurology · doi:10.1177/08830738251374539 · Cited by 3
“10 Recently published practice considerations suggest a variety of measures to reduce these adverse events, including reducing infection risk, premedication prior to treatment, careful device selection, multidisciplinary team involvement, and implementation of institutional-level processes on…”
Boyd, M. M., Mazur, C., Pribnow, K., Zanon, R. L., Adams, E., DuGal, J., Klein, S., & Shafer, L. L. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102742 · Cited by 7
“6,7 While the IT-L route has demonstrated utility in diseases with spinal cord pathology, further assessment of its utility in diseases with pathology in deep brain regions is necessary.”
Early Symptoms and Treatment Outcomes in Neuronal Ceroid Lipofuscinosis Type 2: Croatian Experience
Nišević, J. R., Kolić, I., Kostanjski, M., Kovačević, F., & Prpić, I. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14080783 · Cited by 4
“Key MRI findings could be present at first seizure, but the signs can be subtle and go unrecognized, and be interpreted as “physiological” [17,18].”
BackgroundBerg, A. T., Wojnaroski, M., Ludwig, N. N., Hommer, R., Muzyczka, K., Te, S., Conecker, G., Hecker, J., Nesbitt, G., & Downs, J. A. (2025) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2025.09.005 · Cited by 5
Holla, V. V., Jha, S., Pal, P. K., Yadav, R., Phulpagar, P., Muthusamy, B., & Arunachal, G. (2021) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2021.12.006 · Cited by 4
Clinical and biochemical footprints of inherited metabolic diseases: Ia. Movement disorders, updated
Peacock, D. J. S. J., Ferreira, C. R., Horvath, G. A., Hoffmann, G. F., Blau, N., & Ebrahimi‐Fakhari, D. (2025) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2025.109084 · Cited by 4
Metadata
- Authors
- Schulz, A., Ajayi, T., Specchio, N., de Los Reyes, E., Gissen, P., Ballon, D., Dyke, J. P., Cahan, H., Slasor, P., Jacoby, D., & Kohlschütter, A.
- Affiliations
- Nationwide Children's Hospital (US)
- From the Department of Pediatrics, University Medical Center Hamburg–Eppendorf, Hamburg, Germany (A.S., A.K.); BioMarin Pharmaceutical, Novato, CA (T.A., H.C., P.S., D.J.); the Department of Neuroscience, Bambino Gesù Children’s Hospital, IRCCS, Rome (N.S.); Nationwide Children’s Hospital and Ohio State University, Columbus (E.L.R.); UCL Great Ormond Street Institute of Child Health, London (P.G.); and the Citigroup Biomedical Imaging Center, Departments of Radiology and Genetic Medicine, Weill...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-05-17
- Volume
- 378
- Issue
- 20
- Pages
- 1898-1907
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2799850385
- Cited by
- 489
- References
- 17
- Citations by year
- 2026: 36 · 2025: 57 · 2024: 37 · 2023: 49 · 2022: 86 · 2021: 74 · 2020: 83 · 2019: 47 · 2018: 17
- FWCI
- 37.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- National Institute for Health Research
- European Union Seventh Framework Program Grand (281234)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Glycogen Storage Diseases and Myoclonus
- Keywords
- cerliponase alfa, CLN2 disease, neuronal ceroid lipofuscinosis type 2, intraventricular infusion, enzyme replacement therapy, tripeptidyl peptidase 1, lysosomal storage disease, pediatric patients, device-related infection, adverse events
- MeSH terms
- Tripeptidyl-Peptidase 1, Adolescent, Child, Child, Preschool, Dementia, Dipeptidyl-Peptidases and Tripeptidyl-Peptidases, Female, Humans, Language Development, Male, Motor Skills, Neuronal Ceroid-Lipofuscinoses, Recombinant Proteins, Disease Progression, Kaplan-Meier Estimate, Enzyme Replacement Therapy, Infusions, Intraventricular, Historically Controlled Study
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.